Drug Trial Radar · NCT06455826
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Jun 13, 2024
Primary completion
Sep 24, 2025
Study completion Sep 24, 2025
Sponsor
- Lead sponsor
- PYC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Conditions
- Retinitis Pigmentosa 11
- Retinal Degeneration
- Eye Diseases
- Retinal Disease
- Retinal Dystrophies
Interventions
VP-001Drug
A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence, severity, and relatedness of treatment-emergent ocular adverse events and treatment-emergent serious adverse eventsTime frame: over a 4-week post-dose period
- The incidence, severity, and relatedness of treatment-emergent ocular adverse eventsTime frame: over a 52-week period
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Florida Health
Jacksonville, Florida
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan
Oregon Health and Science University - Casey Eye Institute
Portland, Oregon
Retina Foundation of the Southwest
Dallas, Texas
Baylor College of Medicine- Alkek Eye Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.